Between the excess of life sciences lab space on the market today and significant federal funding cuts threatening support for core research, most biotech builders aren’t in expansion mode. Which ...
The U.S. life sciences real estate market has proven its resiliency after a year of simmering doubts and concerns. But there are serious challenges in 2024 as an ominously large amount of lab and ...
Attend to gain insights into stalled lab leasing, slowed VC and grant funding, high lab buildout costs, and the two tier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback